Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
2
|
| pubmed:dateCreated |
1987-5-1
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Feb
|
| pubmed:issn |
0022-1597
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
38
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
135-6
|
| pubmed:dateRevised |
2009-11-11
|
| pubmed:meshHeading |
pubmed-meshheading:3557337-Combined Modality Therapy,
pubmed-meshheading:3557337-Depressive Disorder,
pubmed-meshheading:3557337-Humans,
pubmed-meshheading:3557337-Imipramine,
pubmed-meshheading:3557337-National Institute of Mental Health (U.S.),
pubmed-meshheading:3557337-Recurrence,
pubmed-meshheading:3557337-Research,
pubmed-meshheading:3557337-Schizophrenia,
pubmed-meshheading:3557337-United States
|
| pubmed:year |
1987
|
| pubmed:articleTitle |
Schizophrenia research heads NIMH priorities.
|
| pubmed:publicationType |
Journal Article
|